MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Subscribe To Our Newsletter & Stay Updated
